Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Clinical Value of Biosimilars and the Role of Interchangeability
A panelist discusses how biosimilar adoption faces multiple barriers despite proven cost benefits, exploring strategies for improving uptake, best practices for interchangeability, experiences with adalimumab switching, and future optimization opportunities in healthcare systems.
Now Viewing
EP: 1.Clinical Value of Biosimilars and the Role of Interchangeability
EP: 2.The Economic Impact of Biosimilars
EP: 3.Best Practices for Employers to Maximize Uptake of Biosimilars
EP: 4.The Role of Private Label Agreements in Enhancing Access to Biosimilars
EP: 5.Key Structural and Operational Considerations for Biosimilar Adoption
EP: 6.Positioning Biosimilars in Clinical Practice
EP: 7.Assessing Patient Confidence With Biosimilars
EP: 8.The Role of Different Stakeholders in Optimizing the Uptake of Biosimilars
EP: 9.The Growing Market for Biosimilars
EP: 10.Biosimilar Pricing Strategies: Understanding High-WAC and Low-WAC Models
EP: 11.The Biosimilar Shift: How PBMs Are Reshaping Formularies
EP: 12.The Road to Biosimilar Adoption: Navigating Interchangeability
EP: 13.How the IRA is Reshaping Biosimilar Adoption
EP: 14.Cost Savings Potential Associated With the Use of Biosimilars
EP: 15.Examining the Role of Interchangeability in Clinical Practice
EP: 16.Optimizing the Implementation of Biosimilars Into Formularies
EP: 17.Key Pearls for Collaborating With Manufacturers for Successful Uptake of Biosimilars
EP: 18.Working With Policy Makers to Effectively Implement Biosimilars
Video content above is prompted by the following:
- Biosimilars have been shown to reduce costs for patients and the healthcare system in general. Given that, why do you think the uptake of biosimilars is still relatively low?
- How can the uptake of biosimilars into health systems be improved?
- Interchangeability can be employed by pharmacists to switch a reference product with a biosimilar. What are your best practices for employing this in your practice?
- What has your experience been like switching from adalimumab reference product to biosimilars?
- How can switching from adalimumab reference product to biosimilars be improved in the future?
Related Videos
Related Content
Missed Opportunities for Salpingectomy Highlight Gaps in Ovarian Cancer Prevention
August 27th 2025Article
Many patients later diagnosed with high-grade serous cancer had prior surgical or genetic testing opportunities that could have reduced their ovarian cancer risk, underscoring the need to expand opportunistic salpingectomy and preventive strategies.
Read More
